A related editorial discusses the findings of this study suggesting that based on available data showing very low event rates of NOACs versus conventional vitamin K antagonist regimens, NOACs seem to be safe and effective first-line agents for patients with atrial fibrillation undergoing elective cardioversion, irrespective of transesophageal echocardiogram-guided strategy or prior anticoagulation status.